Technology
Health
Biotechnology

OpGen

$1.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-3.64%) Today
-$0.04 (-3.64%) Today

Why Robinhood?

You can buy or sell OpGen and other stocks, options, ETFs, and crypto commission-free!

About

OpGen, Inc. engages in the development of molecular information products and services for global healthcare settings. It helps to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). Read More The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.

Employees
50
Headquarters
Gaithersburg, Maryland
Founded
2001
Market Cap
9.51M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
220.55K
High Today
$1.11
Low Today
$1.05
Open Price
$1.11
Volume
35.73K
52 Week High
$2.90
52 Week Low
$0.76

Collections

Technology
Health
Biotechnology
Healthcare
2015 IPO
US
North America

News

MarketBeatMar 10

NASDAQ:OPGN - Stock Price, News, & Analysis for OpGen

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Pa...

23
Seeking AlphaMar 2

OpGen files for $6.5M stock offering

OpGen (NASDAQ:OPGN) has filed a preliminary prospectus for a $6.5M offering of common stock. Price, volume and terms have yet to be announced....

244
Guru FocusFeb 27

OpGen Inc (OPGN) Files 10-K for the Fiscal Year Ended on December 31, 2018

OpGen Inc (NASDAQ:OPGN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. OpGen Inc is an precision medicine company using molecular diagnostics and bioinformatics to help combat infectious disease.

0

Earnings

-$1.38
-$0.94
-$0.51
-$0.07
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.